Objective To analyze the application value and safety of intra-aortic balloon pump (IABP) in septic cardiomyopathy. Methods A retrospective analysis was performed on the clinical data of 90 patients with septic cardiomyopathy admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University from January 2020 to January 2024, 42 patients who received conventional drug therapy were assigned to the control group, and 48 patients who received conventional drug therapy combined with IABP adjuvant therapy were assigned to the observation group. The following items were compared between the two group, including the general data; cardiac function indexes, myocardial injury markers, lactic acid level, and vasoactive-inotropic score (VIS) before and after treatment; mortality rate within 30 days after treatment; and the occurrence of adverse reactions. Results There was no statistically significant difference in the general data between the two groups (all P>0.05). Before treatment, there was no statistically significant difference in the left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), serum creatine kinase isoenzyme (CK-MB) level, serum cardiac troponin Ⅰ(cTnⅠ) level, lactic acid level, or VIS between the two groups (all P>0.05). After treatment, the LVEDDs in the two groups were decreased compared with those before treatment, and the LVEDD in the observation group was smaller than that in the control group; the LVEFs of the two groups were higher than those before treatment, and the LVEF of the observation group was higher than that of the control group (all P<0.05); the CK-MB and cTnⅠ levels in the observation group were lower than those before treatment, and both were lower than those in the control group (all P<0.05); the lactic acid level and VIS in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (all P<0.05). There was no statistically significant difference in the mortality rate within 30 days after treatment between the two groups (52.38% vs. 41.67%) (P>0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (4.76% vs. 12.51%) (P>0.05). Conclusion In the treatment of patients with septic cardiomyopathy, the combination of conventional drugs and IABP can effectively reduce myocardial injury, promote the recovery of cardiac function, and improve hemodynamic status and tissue and organ perfusion, with a high safety.

无